Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 54,000 shares of Akebia’s common stock on August 31, 2020, as inducements material to each such employee’s entering into employment with Akebia.
September 2, 2020
· 1 min read